CORT News

Corcept präsentiert vollständige Daten aus der zulassungsrelevanten ROSELLA-Studie im Rahmen einer Late-Breaker-Präsentation auf der SGO-Konferenz, begleitet von einer gleichzeitigen Veröffentlichung in The Lancet: Lifyorli™ (Relacorilant) Plus...

Corcept présente les données complètes de l'essai pivot ROSELLA dans le cadre d'une présentation de dernière minute au congrès de la SGO, avec une publication simultanée dans The Lancet : Lifyorli™ (rélacorilant) plus nab-paclitaxel améliore la…

Corcept presenta en el Congreso de la SGO los resultados completos del ensayo clínico ROSELLA, publicados simultáneamente en The Lancet: Lifyorli™ (relacorilant) en combinación con nab-paclitaxel prolonga la supervivencia de pacientes con cáncer...

Corcept presenteert volledige gegevens van het cruciale ROSELLA-onderzoek tijdens de SGO late-breaker sessie, met gelijktijdige publicatie in The Lancet: Lifyorli™ (relacorilant) in combinatie met nab-paclitaxel verbetert de totale overleving bij...

Corcept presenta i dati completi dello studio clinico di fase III ROSELLA nelle notizie dell'ultima ora dell'SGO con la pubblicazione simultanea in The Lancet: Lifyorli™ (relacorilant) in combinazione con nab-paclitaxel migliora la sopravvivenza...

Corcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CORT

CORT DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages Corcept Therapeutics Incorporated Investors With Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action - CORT

DEADLINE ALERT for KD, PYPL, SMR, and CORT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

CORT Stockholders Have Opportunity to Lead Corcept Therapeutics Incorporated Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!